{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is predicted to function as a stress responsive protein scaffold mediating the regulation of mitogen activating protein kinase (MAPK) pathways. Mutations in LRRK2, such as Y1699C, result in the onset of parkinsonian symptoms with clinical features indistinguishable from idiopathic Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism related to LRRK2 mutations and their impact on stress response and MAPK pathways."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study used cell viability assays (WST-1 and LDH) and Western blotting to assess the impact of LRRK2 mutations on oxidative stress tolerance and ERK pathway activation.",
          "judgment": "Yes",
          "reasoning": "The assays used are appropriate for modeling the disease mechanism involving oxidative stress and MAPK pathway dysregulation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study included controls (wild-type LRRK2 and parental vector pCDNA3.1) and performed experiments in multiple replicates (at least 2-3 independent experiments with 6-8 replicates each).",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were adequately described, meeting the criteria for assay validity.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compared the effects of Y1699C mutant with wild-type LRRK2 and another mutant (G2019S) as controls.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used, including known pathogenic variants (G2019S) and wild-type LRRK2.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Statistical analyses (ANOVA and post hoc Fisher's PLSD tests) were performed, showing significant differences in cell viability and ERK activation between wild-type and mutant LRRK2.",
          "judgment": "Yes",
          "reasoning": "Statistical analyses were sufficient to support the findings, though OddsPath was not explicitly calculated.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used at least two pathogenic variant controls (Y1699C and G2019S) and wild-type LRRK2 as a benign control.",
          "judgment": "Yes",
          "reasoning": "Although the total number of variant controls is less than 11, the consistent findings across multiple assays support the pathogenic impact of Y1699C.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The Y1699C mutation in LRRK2 shows a loss of protective function against oxidative stress, supported by cell viability assays and ERK pathway analysis. The evidence meets the criteria for PS3_supporting due to the use of appropriate controls and replicates, though the number of variant controls is limited."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is involved in stress-induced signaling cascades mediating cell death. Mutations like G2019S are linked to parkinsonian symptoms.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism related to LRRK2 mutations and their impact on stress response is clearly defined."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study used cell viability assays and Western blotting to assess the impact of G2019S on oxidative stress tolerance and ERK pathway activation.",
          "judgment": "Yes",
          "reasoning": "The assays are appropriate for modeling the disease mechanism involving oxidative stress and MAPK pathway dysregulation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Controls (wild-type LRRK2 and parental vector pCDNA3.1) and multiple replicates were used.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were adequately described.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study compared G2019S with wild-type LRRK2 and another mutant (Y1699C) as controls.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used, including known pathogenic variants (Y1699C) and wild-type LRRK2.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Statistical analyses showed significant differences in cell viability and ERK activation between wild-type and G2019S mutant.",
          "judgment": "Yes",
          "reasoning": "Statistical analyses support the findings, though OddsPath was not explicitly calculated.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used at least two pathogenic variant controls (G2019S and Y1699C) and wild-type LRRK2 as a benign control.",
          "judgment": "Yes",
          "reasoning": "The consistent findings across assays support the pathogenic impact of G2019S, though the number of variant controls is limited.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The G2019S mutation in LRRK2 demonstrates a loss of protective function against oxidative stress, supported by cell viability assays and ERK pathway analysis. The evidence meets the criteria for PS3_supporting due to appropriate controls and replicates, though the number of variant controls is limited."
    }
  ]
}